A research company built around the work of advancing promising molecules toward medicine. NSS-01 is our lead preclinical oncology program.
Patients and families need better options. Our role is to ask useful scientific questions, develop the evidence, and find the right path forward for NSS-01.
Based in Little Rock, Arkansas, Natural State Science has spent more than five years developing NSS-01, including through contract research agreements. Pancreatic and colorectal cancer are co-equal therapeutic priorities.
We welcome discussions about licensing, acquisition of the NSS-01 program, or co-development to advance the program toward clinical development.
Bryce leads program development and strategic partnering. His background includes clinical research at Arkansas Children’s Hospital and experience in rare disease and oncology research. From 2013 to 2020, he served as Chief Scientific Officer for two privately owned clinical research organizations in the pharmaceutical research sector.
Contact BryceKimo brings a pediatric oncology background and experience as a bench scientist. He previously served as a professor in the Department of Pediatrics, Section of Hematology/Oncology, at the University of Arkansas for Medical Sciences (UAMS). His background also includes Arkansas Children’s faculty experience and Children’s Oncology Group membership.
Leadership descriptions follow the company’s executive overview, slide 14, published company biography, and company-provided updates.
We welcome licensing, acquisition of the NSS-01 program, or co-development with a pharmaceutical or biotechnology partner to advance NSS-01 toward clinical development.
Explore transaction options